Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurodevelopment and mood stabilizers.

A J Harwood1

  • 1MRC Laboratory for Molecular Cell Biology & Dept of Biology, University College London, London, UK. a.harwood@ucl.ac.uk

Current Molecular Medicine
|August 29, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling psychiatric disorders: from genomic findings to cellular phenotypes.

Molecular psychiatry·2016
Same author

Modeling psychiatric disorders: from genomic findings to cellular phenotypes.

Molecular psychiatry·2016
Same author

The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior.

Molecular pharmacology·2006
Same author

Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.

Molecular pharmacology·2005
Same author

Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited.

Molecular psychiatry·2004
Same author

A molecular cell biology of lithium.

Biochemical Society transactions·2004

Mood disorders and schizophrenia share genetic links and developmental origins. Mood stabilizers like lithium and valproic acid impact cell development and neuronal morphology, suggesting novel therapeutic targets.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Developmental Biology

Background:

  • Mood disorders and schizophrenia exhibit shared genetic susceptibilities, brain structural differences, and therapeutic responses.
  • Aberrant neurodevelopment is implicated in schizophrenia; its role in mood disorders, particularly adult neurogenesis, is under investigation.
  • Common mood stabilizers (lithium, valproic acid, carbamazepine) are teratogenic, impacting animal development and neuronal morphology.

Purpose of the Study:

  • To explore the potential role of neurodevelopmental changes in the origins of mood disorders.
  • To investigate the molecular mechanisms underlying mood stabilizer actions.
  • To determine if glycogen synthase kinase-3 (GSK-3) or inositol signaling pathways are involved in bipolar disorder.

Main Methods:

Related Experiment Videos

  • Review of existing literature on mood disorders, schizophrenia, neurodevelopment, and mood stabilizer mechanisms.
  • Analysis of studies on the effects of lithium, valproic acid (VPA), and carbamazepine on cell development and neuronal morphology.
  • Examination of research on GSK-3, inositol signaling, histone deacetylase (HDAC), prolyl oligopeptidase (PO), and sodium myo-inositol transporter (SMIT).

Main Results:

  • Lithium inhibits GSK-3 and inositol signaling pathways.
  • VPA up-regulates gene expression via HDAC inhibition and reduces GSK-3 activity; its effects vary by cell type.
  • Carbamazepine does not affect GSK-3 but suppresses inositol signaling, as do lithium and VPA.

Conclusions:

  • Mood stabilizers influence fundamental cellular processes, including cell development and neuronal morphology, suggesting a neurodevelopmental basis for mood disorders.
  • Both GSK-3 and inositol signaling are potential molecular targets for mood stabilizers, but their specific roles in bipolar disorder etiology require further elucidation.
  • Understanding these molecular pathways may lead to novel therapeutic strategies for mood disorders.